Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,141 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07680556Recruiting
Exercise to boost immunotherapy for advanced kidney cancer
This trial tests whether adding a structured exercise program to standard immunotherapy can help the treatment work better for people with advanced renal cell carcinoma.
Arnhem, GelderlandAges 18 years+ - NCT06445972RecruitingPhase 1/Phase 2
Testing combination therapies for advanced stomach or esophageal cancer
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
Tucson, ArizonaAges 18 years+ - NCT04429087RecruitingPhase 1
Test of Obrixtamig for DLL3-positive small cell lung tumors
This Phase 1 study tests different doses of obrixtamig in people with small cell lung cancer and other similar neuroendocrine tumors that test positive for a marker called DLL3. It may help doctors understand safety and the best dose, and possibly improve treatment options when standard therapy didn’t work.
Atlanta, GeorgiaAges 18 years+ - NCT06997497RecruitingPhase 3
Study of Calderasib with other drugs for colorectal cancer
This trial tests a new drug called Calderasib combined with targeted therapy or chemotherapy for people with advanced colorectal cancer that has a specific genetic change (KRAS G12C mutation). It may be an option for those who have not had prior treatment for advanced disease.
Los Angeles, CaliforniaAges 18 years+ - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Birmingham, AlabamaAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT05719558RecruitingPhase 1
Study of ASP1002 for adults with solid tumors
This trial tests a new drug called ASP1002, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if ASP1002 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT06234098RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07615348RecruitingPhase 2
CD70 imaging to guide treatment breaks in advanced kidney cancer
This trial tests whether a special type of imaging scan (CD70-targeted PET/CT) can help doctors safely pause treatment in patients with advanced kidney cancer who respond well to standard immunotherapy and targeted therapy. The goal is to reduce unnecessary treatment while keeping the cancer controlled.
Nanjing, JiangsuAges 18 years+ - NCT05957367RecruitingPhase 1/Phase 2
Study drug for advanced GIST tumors with specific gene mutations
This early-phase study tests inlexisertib (a targeted cancer drug) combined with other anticancer treatments in adults with advanced GIST. It is mainly looking for safety and the best way to dose, and it may help tumors that have certain KIT or PDGFRA gene changes.
Los Angeles, CaliforniaAges 18 years+ - NCT07172919RecruitingPhase 2
Continued treatment with sotorasib for KRAS G12C cancer
This study is for people who are already taking the targeted therapy sotorasib (with or without another drug called panitumumab) in an Amgen clinical trial and are still doing well. It lets you keep receiving the same treatment after your original study ends, so you don't have to stop a medicine that is working for you.
Fort Myers, FloridaAges 18 years+ - NCT07673887RecruitingPhase 3
Study of a new drug combo for advanced stomach cancer
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
DoradoAges 18 years+ - NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT07286149RecruitingPhase 1/Phase 2
Study of MK-1084 plus other treatments for lung cancer
This trial tests a new drug (MK-1084) combined with other treatments for people with a specific type of advanced lung cancer (non-small cell, non-squamous) that has a KRAS G12C mutation. It is for those whose cancer has worsened after prior immunotherapy and chemotherapy.
Clermont, FloridaAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT06921707Recruiting
WounDx test for healing decisions in large wounds
This trial tests a new tool called WounDx that helps doctors decide the best way to treat large wounds on arms, legs, or buttocks. It may help your wound heal better by guiding your care.
Birmingham, AlabamaAges 18–65 - NCT04879329RecruitingPhase 2
Study for HER2-positive bladder cancer after limited treatment
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Gilbert, ArizonaAges 18 years+ - NCT06989398Recruiting
ASCEND supervisor training for Dutch small businesses
This trial tests a training program for supervisors in Dutch companies with 10–250 employees. It aims to improve supervisor skills and employee well-being.
AmsterdamAges 18 years+ - NCT07227870RecruitingPhase 2
Study of L19IL2/TNF for advanced basal cell carcinoma
This trial tests a combination drug (L19IL2/TNF) given as injections into skin tumors. It is for people with advanced basal cell carcinoma that has worsened after or cannot tolerate standard treatments.
Tampa, FloridaAges 18 years+ - NCT02896335RecruitingPhase 2
Palbociclib and pembrolizumab for brain metastases
This study tests two drugs, palbociclib and pembrolizumab, for people whose solid tumors (like breast cancer or melanoma) have spread to the brain. The goal is to see if this combination can shrink or slow the growth of brain tumors that are progressing despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT07228442RecruitingPhase 2
Study of L19IL2 and L19TNF for advanced skin cancer
This trial tests a combination of two drugs, L19IL2 and L19TNF, which are injected directly into skin tumors. It is for patients with advanced cutaneous squamous cell carcinoma that has not responded to or cannot tolerate immune checkpoint inhibitor therapy.
Orange, CaliforniaAges 18 years+ - NCT07207824RecruitingPhase 3
Study of a new drug for high-risk bladder cancer
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07307456RecruitingPhase 2
Toripalimab and BCG for high-risk bladder cancer
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,141 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.